If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » New Product Development and Launch » Managing Thought Leader Programs » Support and Communication
Download FREE Excerpt
Graphics, Detailed Process Map
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
This case study reviews the strategy and tactics utilized by Genentech for the Rheumatoid Arthritis (RA) indicated product, Rituxan, to communicate with KOLs regarding a new mechanism of action treatment for moderate-to-severe RA. The company started by using advisory boards early to harvest insights and seed new ideas before turning to communication vehicles such as peer-to-peer discussions and seminars to redefine RA's existing scientific model for the medical community. The approach created understanding and acceptance for Rituxan's new mechanisms of action. Executives and managers can use this study to gain insights into the creation of messages that communicate how a product with a new MOA changes a dominate treatment paradigm.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.